| | 131918-61-1 Basic information More.. |
| Product Name: | Paricalcitol | | Synonyms: | 1α,25-Dihydroxy-19-nor-vitaMin D2;Paricalcitol/ 19-nor-1α,25-dihydroxyergocalciferol;PARICALCITOL (10 MG)F0E3030.997MG/MG(AI);PARICALCITOL;19-nor-1alpha,25-dihydroxyvitamin D2;(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-Hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol;1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-;Paricalcitol, >=98% | | CAS: | 131918-61-1 | | MF: | C27H44O3 | | MW: | 416.65 | | EINECS: | 658-064-6 | | Mol File: | 131918-61-1.mol |  |
Use
Paricalcitol was launched as Zemplar in the US for the prevention and
treatment of secondary hyperthyroidism associated with chronic renal failure.
Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue
in which the ring A exocyclic methylene group, typical of all vitamin D
systems, has been replaced by two hydrogen atoms. Paricalcitol is the first
vitamin D analogue marketed for this indication. In patients with chronic renal
failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH)
without a significant difference in the incidence rate for hypercalcemia or
hyperphosphatemia when compared with placebo.
- Paricalcitol
-
- US $0.00-0.00 / g
- 2025-05-01
- CAS:131918-61-1
- Min. Order: 1g
- Purity: 99.0%min. HPLC
- Supply Ability: 10000
- Paricalcitol
-
- US $0.00-0.00 / Kg
- 2024-12-24
- CAS:131918-61-1
- Min. Order: 1Kg
- Purity: 99.9%
- Supply Ability: 20tons
- Paricalcitol
-
- US $147.00-852.00 / mg
- 2024-11-19
- CAS:131918-61-1
- Min. Order:
- Purity: 99.5%
- Supply Ability: 10g
|
|
131918-61-1
Recommend Suppliers |
|